DOSAGE INDEX / SINGLE
KPV
Research, reported schedules and supply planning.
Evaluate KPV intestinal-cell and mouse colitis studies, peptide transport and nanoparticle delivery, with clear distinctions from human treatment evidence.
Source: PeptideDosages.com. Independently written summaries of reported protocols, not validated treatment recommendations. Reviewed for transcription on September 21, 2026.
Research Protocol & Dosage
Source-reported examples · not treatment recommendations
- Amount
- 200–500 micrograms per day
- Frequency
- Once daily
- Cycle / observation period
- 8–12 weeks; source also mentions 16 weeks
- Route / research model
- Subcutaneous
Titration & progression
A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.
Supply & Planning
Compare vial strengths here. A different vial size changes the available material, not the biological dose.
Diluent & formulation
Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.
Vial comparison
No single complete schedule is resolved for this entry. Enter a documented total to compare strengths; the calculator does not select a regimen.
| Vial strength | Vials needed |
|---|---|
| 10 mg | Enter a total |
Enter a positive material total.
Material minimum only: round total material ÷ vial content up to a whole vial. Actual supply may be higher because of single-use packaging, discard dates, dead space or losses. No validated multi-use storage period is assumed.
Reported Research Results
Selected observations from the cited research. Each finding retains its study population, formulation and limitations.
- Dalmasso and colleagues investigated KPV uptake in intestinal epithelial and immune-cell systems. The study linked uptake to the PepT1 transporter and reported reduced inflammatory signaling and cytokine secretion under the tested conditions. It also examined KPV in drinking water in DSS- and TNBS-induced mouse colitis models. [1]
- A separate 2008 study tested KPV in DSS colitis and a T-cell-transfer colitis model. Investigators reported earlier recovery, greater regain of illness-associated body weight and reduced inflammatory tissue changes. Colonic myeloperoxidase activity also decreased. Experiments involving a nonfunctional melanocortin-1 receptor suggested that the effects were at least partly independent of that receptor's signaling. [2]
- A 2017 study loaded KPV into hyaluronic-acid-functionalized nanoparticles and delivered them within a hydrogel system. The investigators reported targeted uptake and improved inflammatory and mucosal outcomes in a mouse colitis model compared with a related delivery system lacking that functionalization. [3]
Sourcing & Vendor Information
No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.
Sources & Further Reading
Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.
Bibliography checked September 22, 2026: 9 entries mapped from 1 source page. Medical and supporting references are retained below; supplier entries are excluded.
- Original 2008 Gastroenterology paper
- Kannengiesser and colleagues, original report
- Original nanoparticle study
- Journal of Pharmaceutical Drug Delivery Research (2022)Further reading · Listed in reference bibliography.
- FASEB Journal (2003)No destination link supplied in the source bibliography.Further reading · Listed in reference bibliography.
- Johns Hopkins Arthritis CenterGeneral guidance · Listed in reference bibliography.
- NCBI Bookshelf (Clinical Procedures)Further reading · Listed in reference bibliography.
- CDC Vaccine AdministrationGeneral guidance · Listed in reference bibliography.
- PMC (Subcutaneous Drug Injection Review)Further reading · Listed in reference bibliography.
Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.